Cohance Lifesciences — 360° view

Cohance Lifesciences, a company in the Pharmaceuticals industry, reported revenue of ₹477 crore and net profit of ₹2.27 crore for the September 2026 quarter.

Cohance Lifesciences (NSE: COHANCE) closed at ₹462.30 on 20 Nov 2026, down 20.6% over the past year. Its market capitalisation is ₹17,689 crore and it trades at 362.4 times earnings.

Share price
₹462.30 (20 Nov 2026)
Market cap
₹17,689 Cr (20 Nov 2026)
P/E
362.40 (20 Nov 2026)
Revenue
₹477 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
5.81% (FY26)
ROE
4.89% (FY26)
Book value
₹102 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹601.85 / ₹266.70 (20 Nov 2026)
1-year return
-20.6% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: COHANCE

Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.